- Home
- SEVN vs CRBU Comparison
SEVN vs CRBU Comparison
Compare SEVN & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | CRBU |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 179.7M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SEVN | CRBU |
|---|---|---|
| Price | $8.13 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.50 | ★ $10.75 |
| AVG Volume (30 Days) | 119.5K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 14.04% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | $1.63 |
| Revenue Next Year | $4.06 | $10.93 |
| P/E Ratio | $7.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $0.73 |
| 52 Week High | $12.85 | $3.53 |
Technical Indicators
Market Signals| Indicator | SEVN | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 53.56 |
| Support Level | $8.05 | $1.70 |
| Resistance Level | $8.95 | $2.26 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 27.89 | 50.91 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.